Assessment of antitumor immunity in breast cancer commonly relies on quantifying tumor-infiltrating lymphocytes (TILs). The authors note that lymphocyte abundance alone may not reflect the functional competence or coordination of adaptive immune responses within the tumor microenvironment. They propose that a separate property—termed immune organization, characterized by the presence of organized lymphoid structures and coordinated humoral and cellular programs—may better capture adaptive antitumor immunity and its clinical relevance.
The study integrates multiple complementary approaches across several breast cancer cohorts. Analyses combined histologic evaluation, transcriptomic profiling, spatial methods, and immune receptor sequencing to examine structural and functional aspects of tumor immunity. The authors used these orthogonal data types to identify tumor features consistent with organized adaptive immune responses and to relate those features to immune repertoire properties, treatment-associated changes, and clinical outcomes. Specific cohort names, patient numbers, and analytic pipelines were not itemized in the source summary.
Immune organization in this work is defined by histologic and molecular evidence of tertiary lymphoid structures (TLS) together with coordinated transcriptional programs representing both humoral and cellular immunity. TLS and these coordinated programs represent a structural and functional dimension distinct from mere immune cell counts: they reflect spatial organization and interaction among antigen-presenting cells, B cells, T cells, and likely other immune constituents necessary for antigen-driven adaptive responses.
Across cohorts, tumors with features of immune organization showed greater diversity of immune receptor repertoires, consistent with broader antigen recognition potential. Furthermore, these tumors exhibited evidence of therapy-induced clonal selection of immune receptors, suggesting that organized intratumoral immune structures support adaptive clonal expansion in response to treatment. These observations link tissue-level organization with measurable molecular signatures of adaptive immunity.
Transcriptomic measures reflective of immune organization retained independent prognostic significance when tested across external cohorts, whereas transcriptomic measures of overall immune infiltration did not maintain independent prognostic value. In other words, the structural and programmatic features that define immune organization better predicted clinical outcome than simple measures of lymphocyte abundance.
Changes in immune organization after treatment were associated with therapeutic response, whereas changes in immune infiltration were not. This distinction indicates that treatment-associated augmentation of organized adaptive immune architecture—rather than increased numbers of infiltrating lymphocytes per se—correlates with favorable response. The study therefore identifies immune organization as a dynamic biomarker that can change with therapy and reflect clinically meaningful immune activation.
The authors argue that immune organization is a clinically measurable and dynamic state of adaptive antitumor immunity with potential applications for prognosis, monitoring treatment response, and informing therapeutic development in breast cancer. Because immune organization captures spatial and functional coordination, it may help stratify patients beyond conventional TIL quantification and could direct strategies to promote intratumoral immune organization.
Limitations in the source summary include lack of detailed cohort sizes, specific statistical effect sizes, and methodological parameters—these details were not reported in the available abstract and preprint summary. Additionally, the manuscript is a preprint and has not completed peer review; findings should therefore be interpreted as preliminary until validated and published after peer review.
The work is a preprint and reports that ethical approval was provided by the Institutional Ethics Committee of Hospital Clinic Barcelona (HCB/2025/1142) and that patient consent procedures were followed. Multiple authors disclosed competing interests, including consulting fees, research funding, stock ownership, advisory roles, and inventor status. Funding sources listed include several cancer research foundations, national research agencies, and the European Union Horizon 2020 program. The authors note the preprint status and caution that the research has not been certified by peer review.